This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second opinions: Discussing the potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine Candidate for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Ticker(s): PCVXWho's the expert?
Institution: Wexford Health Sources, Inc
- General family medicine physician
- Administers 30-50 pneumococcal vaccines per month and is familiar with the data to date on Vaxcytes VAX-24
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
